Clinical features and prognosis of drug-induced liver injury in patients with non-alcoholic fatty liver

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-14)

Sum=0

Feb 27, 2025 (publication date) through Feb 20, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Feb 27, 2025; 17(2): 101741
Published online Feb 27, 2025. doi: 10.4254/wjh.v17.i2.101741

Table 14 Follow-up progression to autoimmune hepatitis in the two groups

	DILI (n = 58)	DILI + NAFL (n = 62)	P value
Development of autoimmune hepatitis (number)	6 (10.3)	7 (11.3)	0.868

DILI: Drug-induced liver injury; NAFL: Nonalcoholic fatty liver.

Citation: Zhao Y, Li JZ, Liu YG, Zhu YJ, Zhang Y, Zheng WW, Ma L, Li J, Wang CY. Clinical features and prognosis of drug-induced liver injury in patients with non-alcoholic fatty liver. World J Hepatol 2025; 17(2): 101741
URL: https://www.wjgnet.com/1948-5182/full/v17/i2/101741.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i2.101741